1887

Abstract

Summary

Monoclonal antibodies to the envelope proteins (E) of the 17D vaccine strain of yellow fever virus (17D YF) and to dengue 2 virus were examined for their ability to confer passive protection against lethal 17D YF encephalitis in mice. All 13 IgG anti-17D YF antibodies, regardless of neutralizing capacity, conferred solid protection when given in a relatively high dose prior to intracerebral inoculation of virus. Three antibodies with high neutralizing titres were all protective at a low dose as were several non-neutralizing antibodies. One flavivirus group-reactive antibody to dengue 2 virus conferred similar protection at low dose. Protection was also observed when antibodies were given several days after virus inoculation when peak infectious virus titres and histopathological evidence of infection were present in brains. The ability of a non-neutralizing antibody to protect could not be attributed to complement-dependent lysis of virus-infected cells and did not correlate with avidity or with proximity of its binding site to a critical neutralizing epitope of the E protein. Some antibodies, characterized as non-neutralizing by plaque reduction assay on Vero cells, inhibited the growth of virus in a mouse neuroblastoma cell line, suggesting one possible mechanism of protection. These results may be relevant to the design of prospective flavivirus vaccines and support the possibility of conferring broadened protection among flaviviruses by stimulating the antibody response to appropriate epitopes of the E protein.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-67-2-229
1986-02-01
2024-05-04
Loading full text...

Full text loading...

/deliver/fulltext/jgv/67/2/JV0670020229.html?itemId=/content/journal/jgv/10.1099/0022-1317-67-2-229&mimeType=html&fmt=ahah

References

  1. Boere W. A. M., Benaissa-Trouw B. J., Harmsen T., Erich T., Kraaijeveld C. A., Snippe H. 1985; Mechanisms of monoclonal antibody-mediated protection against virulent Semliki Forest virus. Journal of Virology 52:575–582
    [Google Scholar]
  2. Camenga D. L., Nathanson N., Cole G. A. 1974; Cyclophosphamide-potentiated West Nile viral encephalitis: relative influence of cellular and humoral factors. Journal of Infectious Diseases 130:634–641
    [Google Scholar]
  3. Gentry M. K., Henchal E. A., Mccown J. M., Brandt W. E., Dalrymple J. M. 1982; Identification of distinct antigenic determinants on dengue-2 virus by using monoclonal antibodies. American Journal of Tropical Medicine and Hygiene 31:548–555
    [Google Scholar]
  4. Griffin D. E., Johnson R. T. 1977; Role of the immune response in recovery from Sindbis virus encephalitis in mice. Journal of Immunology 118:1070–1075
    [Google Scholar]
  5. Halstead S. B., Venkatesha C. N., Gentry M. K., Larsen L. K. 1984; Heterogeneity of infection enhancement of dengue 2 strains by monoclonal antibodies. Journal of Immunology 132:1529–1532
    [Google Scholar]
  6. Heinz F. X., Berger R., Tuma W., Kunz C. 1983; A topological and functional model of epitopes on the structural glycoprotein of tick-borne encephalitis virus defined by monoclonal antibodies. Virology 126:525–537
    [Google Scholar]
  7. Henchal E. A., Gentry M. K., Mccown J. M., Brandt W. E. 1982; Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. American Journal of Tropical Medicine and Hygiene 31:830–836
    [Google Scholar]
  8. Mathews J. H., Roehrig J. T. 1982; Determination of the protective epitopes on the glycoproteins of Venezuelan equine encephalomyelitis virus by passive transfer of monoclonal antibodies. Journal of Immunology 129:2763–2767
    [Google Scholar]
  9. Mathews J. H., Roehrig J. T. 1984; Elucidation of the topography and determination of the protective epitopes on the E glycoprotein of St. Louis encephalitis virus by passive transfer with monoclonal antibodies. Journal of Immunology 132:1533–1537
    [Google Scholar]
  10. Monath T. P., Schlesinger J. J., Brandriss M. W., Cropp C. B., Prange W. C. 1984; Yellow fever monoclonal antibodies: type-specific and cross-reactive determinants identified by immunofluorescence. American Journal of Tropical Medicine and Hygiene 33:695–698
    [Google Scholar]
  11. Porterfield J. S. 1980; Antigenic characteristics and classification of Togaviridae. In The Togaviruses–Biology, Structure and Replication pp. 13–46 Edited by Schlesinger R. W. New York: Academic Press;
    [Google Scholar]
  12. Schlesinger J. J., Brandriss M. W. 1983; 17D yellow fever virus infection of P388D, cells mediated by monoclonal antibodies: properties of the macrophage Fc receptor. Journal of General Virology 64:1255–1262
    [Google Scholar]
  13. Schlesinger J. J., Brandriss M. W., Monath T. P. 1983; Monoclonal antibodies distinguish between wild and vaccine strains of yellow fever virus by neutralization, hemagglutination inhibition, and immune precipitation of the virus envelope protein. Virology 125:8–17
    [Google Scholar]
  14. Schlesinger J. J., Walsh E. E., Brandriss M. W. 1984; Analysis of 17D yellow fever virus envelope protein epitopes using monoclonal antibodies. Journal of General Virology 65:1637–1644
    [Google Scholar]
  15. Schlesinger J. J., Brandriss M. W., Walsh E. E. 1985; Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48. Journal of Immunology 135:2805–2809
    [Google Scholar]
  16. Schmaljohn A. L., Johnson E. D., Dalrymple J. M., Cole G. A. 1982; Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis. Nature, London 297:70–72
    [Google Scholar]
  17. Zisman B., Wheelock E. F., Allison A. C. 1971; Role of macrophages and antibody in resistance of mice against yellow fever virus. Journal of Immunology 107:236–243
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-67-2-229
Loading
/content/journal/jgv/10.1099/0022-1317-67-2-229
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error